UnitedHealthcare Medicare Advantage Reimbursement Policy — Fecal Analysis Testing
Defines UnitedHealthcare Medicare Advantage reimbursement stance and methodology for fecal analysis testing used to evaluate intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth; applies to UnitedHealthcare Medicare Advantage claims processing.
Policy language and code update in Reimbursement Guidelines section.
Coverage Determinations
Exclusion of reimbursement for fecal analysis diagnostic testing
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.